蝶腭神经阻滞治疗颅面多汗与潮红的随机试验
一项随机试验将25例颅面多汗(CFH)患者按1:3分为表面利多卡因组(TL,n=7)和蝶腭神经节注射利多卡因组(IL,n=18),评估两种阻滞方法对CFH和潮红的影响。6个月后IL组CFH VAS最小二乘均值变化为-38.1(-47.3至-28.9),TL组为1.9(-12.2至15.9),但潮红VAS无改善,鼻科指标及生活质量无显著变化。结论认为注射阻滞安全且CFH改善持续6个月,但样本量小且缺乏客观指标,需更多研究。
要点
- 蝶腭神经节注射利多卡因可显著改善颅面多汗VAS评分,效果持续6个月。
- 潮红VAS、鼻科指标及生活质量量表在两组均无显著变化。
- 注射组术中1例出现可控鼻出血,总体安全性良好。
核心结论
- 蝶腭神经节注射利多卡因是安全操作,CFH患者VAS显著改善并持续6个月。
- 潮红VAS未改善,鼻科测量及生活质量测试无显著变化。
- 因样本量小且缺乏客观指标,需更多研究验证。
研究设计与样本
- 随机对照试验,25例CFH患者按1:3随机分为TL组(n=7)和IL组(n=18)。
- TL组内镜下蝶腭神经节表面涂抹利多卡因,IL组内镜下注射利多卡因。
- 在0、1、3、6个月随访评估VAS及多项鼻科、眼表、生活质量问卷。
主要发现
- 基线CFH VAS:TL组89.3±17.5mm,IL组85.7±22.1mm;潮红VAS:TL组52.7±30mm,IL组59±33.8mm。
- 6个月时CFH VAS最小二乘均值变化:IL组-38.1(-47.3至-28.9),TL组1.9(-12.2至15.9)。
- 潮红VAS未改善,任何鼻科测量或生活质量测试均无显著变化。
- IL组术中1例出现可控鼻出血。
临床怎么用
- 对于颅面多汗患者,可考虑蝶腭神经节注射利多卡因作为安全治疗选项。
- 治疗前应告知潮红可能无改善,且鼻科及生活质量指标预期无显著变化。
- 注射操作需注意术中鼻出血风险,但多为可控。
局限性
- 样本量小(n=25),分组不均(TL组n=7,IL组n=18)。
- 缺乏客观测量指标,主要依赖VAS主观评分。
- 初步研究结论需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Craniofacial hyperhidrosis (CFH) and flushing express nervous system autonomic dysfunction. Available reference treatments lack good compliance. The study objective was to investigate variations of CFH/flushing after two methods of sphenopalatine ganglion (SPG) blockade. METHODOLOGY: CFH patients (n=25) were randomized in a ratio of 1:3 in two groups; 1) endoscopic application of topical lidocaine over SPG (TL; n=7); 2) endoscopic injection of lidocaine in the SPG (IL; n=18). CFH, flushing, rhinorrhoea, nasal obstruction, and smell detection were scored by Visual Analogue Scale (VAS). Nasal endoscopy, acoustic rhinometry, mucociliary transport test, smell/taste test, Schirmer test, Short Form-12, Chronic Skin Diseases Questionnaire, and Skin Satisfaction Questionnaire were also performed at visit 0, 1, 3 and 6 months. RESULTS: At baseline, groups reported similar CFH VAS (TL: 89.3 plus or minus 17.5mm; IL: 85.7 plus or minus 22.1mm) or flushing VAS (TL: 52.7 plus or minus 30mm; IL: 59 plus or minus 33.8mm). After 6 months, the least squares mean of CFH VAS in IL was -38.1 (-47.3 to -28.9) compared to TL 1.9 (-12.2 to 15.9). However, flushing VAS did not improve. Any rhinological measure nor quality of life test showed significant changes. One patient presented controlled epistaxis intraoperatively during IL. CONCLUSIONS: This preliminary study shows the sphenopalatine blockade injection as a safe procedure. Patients with CFH or flushing had significant improvement after lidocaine injection which lasted 6 months. Due to the small sample and the lack of objective measures more studies are needed.
引用
- Lehrer E, Nogues A, Jaume F, et al. Assessment of craniofacial hyperhidrosis and flushing by sphenopalatine blockade - a randomized trial. Rhinology. 2020. PMID: 31475696. doi:10.4193/Rhin19.119
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。